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Effects of Perioperative Nesiritide
in Patients With Left Ventricular
Dysfunction Undergoing Cardiac Surgery
The NAPA Trial
Robert M. Mentzer, JR, MD, FACC,* Mehmet C. Oz, MD, FACC,† Robert N. Sladen, MD, FCCM,‡
Allen H. Graeve, MD, FACS,§ Robert F. Hebeler, JR, MD, John M. Luber, JR, MD, FACS,¶
Nicholas G. Smedira, MD, FACC,# on behalf of the NAPA Investigators
Detroit, Michigan; New York, New York; Tacoma, Washington; Dallas, Texas; and Cleveland, Ohio
Objectives The purpose of this study was to determine the role nesiritide might play in patients with left ventricular dysfunc-
tion undergoing coronary artery bypass grafting (CABG) using cardiopulmonary bypass (CPB).
Background Given the hemodynamic, neurohormonal, and renal effects of natriuretic peptides, nesiritide might be useful in
the management of patients undergoing cardiac surgery.
Methods This prospective, double-blind, exploratory evaluation randomly assigned patients with ejection fraction 40%
who were undergoing CABG with anticipated use of CPB to receive either nesiritide or placebo, in addition to
usual care, for 24 to 96 h after induction of anesthesia. Postoperative renal function, hemodynamics, and drug
use (primary end points) were assessed in patients who underwent CABG using CPB; mortality and safety (sec-
ondary end points) were assessed in all patients who received the study drug.
Results Of 303 randomized patients, 279 received the study drug and 272 underwent CABG using CPB. Compared with
placebo, nesiritide was associated with a significantly attenuated peak increase in serum creatinine (0.15 0.29
mg/dl vs. 0.34  0.48 mg/dl; p  0.001) and a smaller fall in glomerular filtration rate (10.8  19.3 ml/min/1.73
m2 vs. 17.2  21.9 ml/min/1.73 m2; p  0.001) during hospital stay or by study day 14, and a greater urine out-
put (2,926  1,179 ml vs. 2,350  1,066 ml; p  0.001) during the initial 24 h after surgery. In addition, nesiritide-
treated patients had a shorter hospital stay (p 0.043) and lower 180-day mortality (p 0.046).
Conclusions Nesiritide in the setting of CABG with CPB is associated with improved postoperative renal function and possibly
enhanced survival. (The NAPA Trial; http://www.clinicaltrials.gov/ct/show; NCT00090792) (J Am Coll Cardiol
2007;49:716–26) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.10.048a
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sesiritide is recombinant human B-type natriuretic peptide
1). Physiologically, the natriuretic peptides have important
ffects on salt and water balance and vascular tone (2).
See page 727
hen administered to patients with heart failure, nesiritide
ecreases preload, afterload, and pulmonary vascular resis-
ance and increases cardiac output without inducing tachy-
rom the *Division of Cardiothoracic Surgery, Department of Surgery, Wayne State
niversity School of Medicine, Detroit, Michigan; †Division of Cardiothoracic
urgery, College of Physicians & Surgeons, Columbia University, New York, New
ork; ‡Department of Anesthesiology, College of Physicians & Surgeons, Columbia
niversity, New York, New York; §MultiCare Cardiothoracic Surgical Associates,
acoma General Hospital, Tacoma, Washington; Department of Surgery, Baylor
niversity Medical Center, Dallas, Texas; ¶Franciscan Health System Research
enter, Tacoma, Washington; and the #Department of Thoracic and Cardiovascular 2rrhythmias (2–4). In some studies, nesiritide has been
ssociated with increased urine output; reduced diuretic
equirements; and suppression of aldosterone, endothelin,
nd norepinephrine (5,6). Nesiritide therapy effectively
educes pulmonary capillary wedge pressure and relieves
yspnea in patients hospitalized with acute decompensated
eart failure (2–4). Several small, retrospective, and/or
ncontrolled evaluations have suggested beneficial effects in
atients undergoing cardiac surgery (7–9). However, the
urgery, The Cleveland Clinic, Cleveland, Ohio. The NAPA trial was sponsored by
cios Inc. (Fremont, California). Drs. Mentzer and Sladen have received honoraria
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February 13, 2007:716–26 Nesiritide in Cardiac Surgery Patientsole of nesiritide in the management of patients undergoing
oronary artery bypass grafting (CABG) using cardiopul-
onary bypass (CPB) has not been definitively established.
Coronary artery bypass grafting using CPB induces neu-
ohormonal and renal responses that are similar to those
een in acute decompensated heart failure (10). Postopera-
ive renal dysfunction and acute renal failure are frequent
nd serious complications of cardiac surgery (10–13). Sev-
ral observational reports have demonstrated that postoper-
tive renal dysfunction significantly increases morbidity and
ortality and prolongs both intensive care unit (ICU) and
otal hospital length of stay (LOS) (10,12,13). Preoperative
enal dysfunction is also common in CABG patients. In 1
tudy, 78% of CABG patients had at least mild renal
ysfunction, as defined by the National Kidney Foundation,
reoperatively (14). Furthermore, morbidity, mortality, and
OS were all significantly and inversely related to baseline
enal function, even after adjusting for other clinical risk
actors (14). Similarly, renal dysfunction occurs frequently
n association with chronic heart failure (15) and, as in
ABG surgery, adversely impacts prognosis (16).
Consequently, effective strategies for preserving renal
unction postoperatively and improving outcomes in pa-
ients with left ventricular (LV) dysfunction undergoing
ABG might have a substantial clinical impact. Several
harmacologic agents, including N-acetylcysteine, “renal-
ose” dopamine, and fenoldopam, have been assessed and
ound to be ineffective for prevention of postoperative renal
ysfunction (11,17,18). Thus, a major unmet need in the
anagement of these patients persists. The objective of the
APA (Nesiritide Administered Peri-Anesthesia in Pa-
ients Undergoing Cardiac Surgery) trial was to explore the
ffects of nesiritide on postoperative renal function, hemo-
ynamics, clinical outcomes, and safety in patients with LV
ysfunction undergoing CABG using CPB.
ethods
he NAPA trial was a prospective, multicenter, random-
zed, double-blind, placebo-controlled, exploratory study in
atients with chronic LV dysfunction undergoing CABG,
ith or without mitral valve replacement/repair, using CPB.
atients were enrolled at 54 centers throughout the U.S.
ver a 15-month period from March 2004 through May
005 and were followed for 6 months after enrollment.
ligibility requirements included age 18 years, New York
eart Association functional class II to IV heart failure, and
ocumented LV ejection fraction 40% within 90 days
efore surgery. Subjects with planned mitral valve repair or
eplacement at the time of surgery were eligible. However,
ubjects with planned aortic valve repair or replacement
ere excluded. Additional exclusion criteria were: a require-
ent for ongoing or chronic dialysis; presence of restrictive
r obstructive cardiomyopathy, pericarditis, or pericardial
amponade; documented low cardiac filling pressures;
nown congenital heart disease; evidence of ongoing infec- aion; and pulmonary disease,
ncluding chronic obstructive
ulmonary disease or asthma,
equiring hospital stay within 60
ays. All patients provided writ-
en, informed consent before
tudy participation.
tudy protocol. Patients were
andomized to receive either a
xed dose of intravenous nesirit-
de (0.01 g/kg/min without bo-
us) or placebo for a minimum of
4 h in addition to usual periop-
rative and postoperative care.
tudy drug infusion was started
fter induction of anesthesia but
efore chest incision and was continued for a minimum of
4 h up to a maximum of 96 h at the discretion of the
ttending physician. Right heart pressures were assessed
ith a Swan-Ganz catheter placed immediately before the
tart of study drug infusion. Patients with mean pulmonary
ressures consistently 15 mm Hg, central venous pressure
onsistently 6 mm Hg, or systolic blood pressure consis-
ently 90 mm Hg were excluded from further study
articipation. Blood samples for serum creatinine (SCr)
etermination were obtained preoperatively (“baseline”); at
ostoperative hours 0, 6, 12, and 18; and then at ICU and
ospital discharge. Hemodynamic assessments were ob-
ained at baseline and at postoperative hours 0, 6, 12, 18,
nd 24.
nd points. This exploratory study included 5 end points
f interest: 1) change from baseline to peak SCr by the end
f hospital stay or by study day 14 (whichever came first); 2)
hange from baseline glomerular filtration rate (GFR) to the
owest GFR measured during hospital stay or by study day
4 (whichever came first), with GFR calculated using the
odification of Diet in Renal Disease equation (19); 3)
ntravenous inotropic agent/vasopressor and vasodilator use;
) change from baseline in mean pulmonary artery pressure
or 24 h after the start of study drug or until removal of the
wan-Ganz catheter (whichever came first); and 5) urine
utput during the initial 24 h after admission to the ICU or
ntil ICU discharge (whichever came first). Secondary end
oints included: 1) duration of intubation; 2) duration of
tay in the ICU; 3) total hospital LOS; 4) change from
aseline in mean pulmonary capillary wedge pressure, cen-
ral venous pressure, cardiac index, and systemic vascular
esistance; and 5) 30- and 180-day mortality and drug
afety.
tatistical analysis. The change from baseline to postop-
rative peak SCr was compared using an analysis of covari-
nce model, with treatment group as qualitative factor and
aseline SCr value as covariate, as well as using a non-
arametric Wilcoxon rank-sum test. The change in GFR
as analyzed similarly. Urine outputs were compared using
Abbreviations
and Acronyms
CABG  coronary artery
bypass grafting
CI  confidence interval
CPB  cardiopulmonary
bypass
GFR  glomerular filtration
rate
HR  hazard ratio
ICU  intensive care unit
LOS  length of stay
LV  left ventricular
SCr  serum creatinine1-way analysis of variance model. Analyses of change in
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Nesiritide in Cardiac Surgery Patients February 13, 2007:716–26ulmonary and systemic hemodynamic parameters were
erformed using a 1-way analysis of covariance model, with
he baseline value as covariate. Temporal changes in SCr
nd hemodynamic parameters were analyzed using longitu-
inal repeated measures analysis of variance model. Use of
oncomitant medications was compared using analysis of
ariance for continuous variables and chi-square or Fisher
xact test for categorical variables. The ICU LOS and
ospital LOS were analyzed using the Wilcoxon rank-sum
est, owing to the non-normality of the data. Kaplan-Meier
stimates and log-rank tests were performed for the mor-
ality rates comparison. Hazard ratios (HRs) were computed
t day 30 and day 180 using the Cox proportional hazard
odel. All tests were 2-sided with p values 0.05 consid-
red significant. Because this was a pilot study, formal
djustment for multiplicity was not made. Unless otherwise
oted, all summary statistics for continuous variables are
resented as mean  SD.
esults
atient enrollment. Initially, 303 patients were random-
zed; perioperative hemodynamics (n  10) and other
actors (rescheduled surgery: n 4; decision not to use CPB
efore administration of study drug: n  3; withdrawn
onsent: n  3; and failure to meet other entry criteria:
 4) precluded study drug administration in 24 of these
atients, and 7 patients who received study drug ultimately
nderwent surgery without CPB (Fig. 1). The remaining
72 patients (nesiritide: n  137; placebo: n  135)
onstitute the “efficacy population,” which was used for all
utcome evaluations except mortality and safety. Mortality
at 30 and 180 days) and safety (within 30 days) were
Figure 1 Analysis Populations
Consort diagram depicting the progress of the randomized patients over the coursssessed in all 279 patients (nesiritide: n  141; placebo: n
138) who received study drug regardless of CPB use.
aseline characteristics and surgical procedures. Mean
ge of the study population was 64  11 years; 219 (78%)
ere men and 232 (83%) were white. There were no
ignificant differences between the 2 study groups with
espect to baseline demographic and clinical characteris-
ics (Table 1). Mean LV ejection fraction at baseline was
9.9%, and mean baseline blood B-type natriuretic pep-
ide level was 418 pg/ml. Concomitant oral medications
or heart failure (medications prescribed at any time from
nformed consent through the end of the study) were
imilar between the groups and included angiotensin-
onverting enzyme inhibitors (76%), angiotensin II re-
eptor blockers (8%), beta-blockers (96%), and loop
iuretics (68%). Surgical procedures were similar between
he 2 study groups (Table 2).
tudy drug administration. The mean duration of study
rug infusion was 39.4  21.6 h in the nesiritide group and
0.6  23.4 h in the placebo group (p  0.67 with analysis
f variance); the median infusion durations were 29.1 and
0.1 h, respectively. Total infusion duration was 24 h in
3% of nesiritide and 11% of placebo patients, 24 but
48 h in 60% of nesiritide and 61% of placebo patients,
48 but 72 h in 16% of nesiritide and 15% of placebo
atients, and72 h in 11% of nesiritide and 13% of placebo
atients. During the infusion period, 13 (9.2%) nesiritide
nd 11 (8.0%) placebo patients (p  0.83) had a reduction
n study drug dose, primarily for hypotension. None of these
eductions were due to changes in SCr or GFR.
fficacy. Although mean SCr increased postoperatively in
oth groups, the increase was attenuated in patients receiv-
e trial and their contribution to the various analysis groups.e of th
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February 13, 2007:716–26 Nesiritide in Cardiac Surgery Patientsng nesiritide. In the nesiritide patients, mean SCr returned
o baseline by 12 h after ICU admission and remained there
hroughout the remainder of the hospital stay. In placebo
atients, however, mean SCr was elevated significantly
elative to baseline within 12 h of ICU admission, and this
levation persisted through the hospital stay (Fig. 2). The
aximum absolute increase in SCr and absolute decline in
FR during hospital stay or by study day 14 (whichever
ame first) were significantly less in nesiritide patients
ompared with placebo patients with either parametric (Fig.
) or non-parametric analyses (data not shown). Relative to
aseline, SCr increased 17  29% in nesiritide and 33 
6% in placebo patients, and GFR decreased 11  22% in
esiritide and 20  24% in placebo patients. The effects of
esiritide on postoperative renal dysfunction were especially
ronounced in patients with renal dysfunction at baseline
Demographic and Clinical Characteristics at Ba
Table 1 Demographic and Clinical Characte
Characteristic
Age, yrs
Male gender, n (%)
Race/ethnicity, n (%)
White
Black
Hispanic
Other
Weight, kg
New York Heart Association functional class, n (%)
I
II
III
IV
Left ventricular ejection fraction, %
BNP, pg/ml
N-terminal pro-BNP, pg/ml
Medical history, n (%)†
Non–insulin-dependent diabetes mellitus
Insulin-dependent diabetes mellitus
Chronic obstructive pulmonary disease
Other pulmonary disease
Reactive precapillary pulmonary hypertension
Mild liver disease
Anemia
Peripheral vascular disease
Diabetic nephropathy
Other chronic renal disease
Renal function
Serum creatinine, mg/dl
Blood urea nitrogen, mg/dl
Glomerular filtration rate, ml/min/1.73 m2
Hemodynamics
Mean systolic blood pressure, mm Hg
Mean pulmonary artery pressure, mm Hg
*Differences between placebo and nesiritide groups are all non-signific
variables). †As reported by the attending physician.
BNP  B-type natriuretic peptide.seline
ristics at Baseline
Placebo Nesiritide*
(n  138) (n  141)
64.1  11.3 63.6  10.5
108 (78) 111 (79)
117 (85) 115 (82)
9 (7) 10 (7)
10 (7) 11 (8)
2 (1) 5 (4)
89.2  21.7 86.9  19.6
1 (1) 0 (0)
71 (51) 64 (45)
52 (38) 62 (44)
13 (9) 14 (10)
30.1  7.3 29.7  7.5
406  511 431  615
3026  4224 2877  4802
43 (31) 45 (32)
26 (19) 23 (16)
25 (18) 25 (18)
17 (12) 21 (15)
7 (5) 5 (4)
5 (4) 5 (4)
24 (17) 27 (19)
30 (22) 29 (21)
8 (6) 6 (4)
33 (25) 28 (21)
1.11  0.44 1.07  0.40
22.4  8.8 22.5  11.3
77.6  28.1 82.0  30.3
120  21 122  21
25.4  8.8 25.6  8.7
ant (analysis of variance continuous variables and chi-square for categoricaldefined as baseline SCr 1.2 mg/dl) (Fig. 3). In these
*urgical Procedures
Table 2 Surgical Procedures
Placebo Nesiritide
(n  138) (n  141)
Coronary artery bypass grafting alone, n (%) 92 (67) 96 (68)
Concomitant procedures, n (%)*
Mitral valve repair 24 (17) 21 (15)
Mitral valve replacement 4 (3) 4 (3)
Maze procedure 5 (4) 7 (5)
Dor procedure 4 (3) 7 (5)
Transmyocardial laser revascularization 2 (1) 0 (0)
Intra-aortic balloon pump 10 (7) 12 (9)
Other 14 (10) 12 (9)
Re-operations (prior CABG) 11 (8) 8 (6)Subjects may have undergone more than one procedure.
CABG  coronary artery bypass graft.
p
i
n
r
s
(
A
a
u
s
A
r
d
D
720 Mentzer, Jr. et al. JACC Vol. 49, No. 6, 2007
Nesiritide in Cardiac Surgery Patients February 13, 2007:716–26atients, SCr increased 3 20% in nesiritide and 29 36%
n placebo patients and GFR increased 1  22% in
esiritide and decreased 19  23% in placebo patients
elative to baseline.
Urine output during the initial 24 h after surgery was
ignificantly greater in nesiritide than in placebo patients
2,926  1,179 ml vs. 2,350  1,066 ml; p  0.001).
lthough the subset of patients who had renal dysfunction
Figure 2 Time Course of SCr Response
Mean change from baseline in postoperative (post-op) serum creatinine (SCr) valu
line) patients. Vertical lines signify 1 SEM. *p  0.05 nesiritide versus placebo o
change from baseline on the basis of paired t test. ICU  intensive care unit.
Figure 3 Maximal Change in SCr and GFR by Baseline Renal Fu
Adjusted mean maximum increase in serum creatinine (SCr) (A, B, and C) and de
through hospital discharge or by study day 14, whichever came first, using an anat baseline is small, there was a significant improvement in
rine output with nesiritide compared with placebo in this
ubset (2,838  1,106 ml vs. 2,251  897 ml; p  0.025).
fter surgery, 80% of nesiritide and 77% of placebo patients
eceived a diuretic, predominantly furosemide (Table 3).
Use of inotropic agents, vasopressors, inodilators, and vaso-
ilators was similar between the groups (Tables 3 and 4).
uring hospital stay, 96% of nesiritide patients and 95% of
r the course of the hospital stay in nesiritide (solid line) and placebo (dotted
basis of longitudinal repeated measures analysis of variance model; †p  0.05
n
in glomerular filtration rate (GFR) (D, E, and F) from baseline
f covariance model. Lines above the bars represent 1 SEM.es ove
n thenctio
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February 13, 2007:716–26 Nesiritide in Cardiac Surgery Patientslacebo patients received an inotropic agent/vasopressor, pre-
ominantly norepinephrine and/or phenylephrine. Almost
ne-half of the patients (nesiritide: 44%; placebo: 47%) re-
eived an inodilator, predominantly milrinone. A median of 3
ifferent inotropic agents/vasopressors/inodilators were used in
oth nesiritide and placebo patients (Table 4).
Changes in hemodynamic parameters over time were
imilar between the treatment groups (Fig. 4). During the
nitial 24 h of study drug administration, mean pulmonary
rtery pressure decreased: 2.8  7.9 mm Hg in nesiritide
nd 1.9  7.8 mm Hg in placebo patients (p  0.297).
ikewise, mean arterial pressure decreased: 5.5  19.5
m Hg in nesiritide and 5.3  19.3 mm Hg in placebo
atients (p  0.958). Cardiac index increased 0.6  0.9
/min/m2 in nesiritide and 0.7  0.7 l/min/m2 in placebo
atients (p  0.429).
Mean ventilation times were 21.8  22.2 h and 29.3 
2.9 h in the nesiritide and placebo groups, respectively (p
0.498). Nesiritide patients had a mean total ICU LOS of
8.8  92.2 h compared with 103.2  156.6 h for placebo
atients (p  0.370) and a total hospital LOS of 9.1  6.1
ays compared with 11.5  9.8 days for placebo patients (p
umber of Patients Receiving Selectedoncomitant Pos operative Cardiovascularedicat ns
Table 3
Number of Patients Receiving Selected
Concomitant Postoperative Cardiovascular
Medications
Placebo Nesiritide*
(n  135) (n  137)
Any, n (%) 135 (100) 137 (100)
Intravenous loop diuretics, n (%) 104 (77) 109 (80)
Furosemide 102 (76) 107 (78)
Bumetanide 18 (13) 14 (10)
Torsemide 2 (1) 0 (0)
Ethacrynic acid 1 (1) 0 (0)
Inotropic agents/vasopressors, n (%) 128 (95) 131 (96)
Norepinephrine 76 (56) 79 (58)
Phenylephrine 70 (52) 67 (49)
Epinephrine 49 (36) 44 (32)
Dobutamine 50 (37) 39 (28)
Dopamine 45 (33) 41 (30)
Vasopressin 32 (24) 28 (20)
Ephedrine 15 (11) 16 (12)
Inodilator 64 (47) 60 (44)
Milrinone 63 (47) 60 (44)
Amrinone 2 (1) 0 (0)
Vasodilators 104 (77) 102 (74)
Glyceryl trinitrate 89 (66) 86 (63)
Nitroprusside 22 (16) 22 (16)
Nicardipine 17 (13) 11 (8)
Hydralazine 16 (12) 10 (7)
Nesiritide† 6 (4) 7 (5)
Nitric oxide 0 (0) 1 (1)
Other
Aprotinin 61 (45%) 64 (47%)
Differences between placebo and nesiritide groups are all non-significant (Fisher exact test).
Reflects protocol-deviation, open-label use of nesiritide.0.043).
*
cafety. MORTALITY. Thirty-day mortality data were
vailable for 132 patients in the nesiritide group and 127
n the placebo group; 180-day mortality data were avail-
ble for 94 and 95 patients, respectively. Survival at 180
ays was significantly greater in patients receiving nesirit-
de (Fig. 5). Thirty days after initiation of the study drug,
(2.8%) nesiritide and 8 (5.9%; p  0.219) placebo
atients had died; all but 1 of these deaths, a placebo
atient, occurred in the hospital. Causes of death in the
nesiritide patients, as determined by the attending
hysician, included: 1) cardiac arrest, 2) multisystem
rgan failure, 3) aortic rupture, and 4) fulminant clos-
ridium difficile colitis. Causes of death in the 8 placebo
atients were: 1) cardiac arrest, 2) ventricular tachycardia
rrest, 3) ventricular fibrillation, 4) probable cardiac
rrhythmia, 5) multisystem organ failure (2 patients), 6)
troke, and 7) dead bowel. By 180 days, 8 (6.6%)
esiritide and 17 (14.7%; p  0.046) placebo patients had
ied. The additional causes of death included multisys-
em organ failure (3 patients) and bacterial meningitis (1
atient) in nesiritide patients and cardiac arrest, heart attack,
eart failure, anoxic encephalopathy, sepsis, cholangitis,
coma,” and unknown (2 patients) in placebo patients. The
ortality HR for nesiritide relative to placebo was 0.48 (95%
onfidence interval [CI] 0.14 to 1.59) at 30 days and 0.44
95% CI 0.19 to 1.01) at 180 days.
DVERSE EVENTS. Adverse events were common, with simi-
ar rates of overall adverse events in each group (Table 5).
erious adverse events occurred in 43 (30.5%) nesiritide and 51
37.0%) placebo patients; only 8 patients (2 [1.4%] nesiritide
nd 6 [4.3%] placebo) had an event thought to be potentially
elated to the study drug. These potentially related adverse
vents were hypotension and ventricular tachycardia in the 2
egree of Postoperative Inotropicnd Vas active Pharmacothera y
Table 4 Degree of Postoperative Inotropicand Vasoactive Pharmacotherapy
Placebo Nesiritide*
(n  135) (n  137)
Inotropic agents/vasopressors/inodilators
Number of different agents used per patient
Mean  SD 3.1  1.5 2.8  1.3
Median 3.0 3.0
Patients receiving, n (%)
0 5 (4) 3 (2)
1 to 3 84 (62) 95 (69)
3 45 (33) 37 (27)
Vasodilators
Number of different agents used per patient
Mean  SD 1.4  0.7 1.3  0.6
Median 1.0 1.0
Patients receiving, n (%)
0 30 (22) 33 (24)
1 to 2 95 (70) 95 (69)
2 9 (7) 7 (5)Differences between placebo and nesiritide groups are all non-significant (analysis of variance for
ontinuous variables and chi-square for categorical variables).
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Nesiritide in Cardiac Surgery Patients February 13, 2007:716–26esiritide patients and hypotension, hypotension with renal
ailure, renal failure, worsening heart failure with cardiac arrest,
trial fibrillation, and confusion in the 6 placebo patients.
iscussion
he results of this exploratory trial suggest that periopera-
ive infusion of nesiritide might have favorable effects in
Figure 4 Time Course of Hemodynamic Parameters During the
Mean pulmonary artery pressure (A), pulmonary capillary wedge pressure (B), mea
vascular resistance (F) at baseline and over the initial 24 postoperative hours in n
ues and vertical lines represent 1 SEM. The p values are for nesiritide versus plaatients with LV dysfunction undergoing CABG using cPB. Patients receiving nesiritide had better overall pres-
rvation of GFR, lower peak increase in SCr levels, and
reater urine output in the immediate postoperative period
ompared with patients receiving placebo. These beneficial
ffects were preserved, if not enhanced, in high-risk patients
ith preexisting renal dysfunction.
Short- and medium-term outcomes after surgical myo-
l 24 Postoperative Hours
rial pressure (C), central venous pressure (D), cardiac index (E), and systemic
de (solid lines) and placebo (dotted lines) patients. Points represent mean val-
omparison using a longitudinal repeated measures analysis of variance model.Initia
n arte
esiriti
cebo cardial revascularization are affected adversely by both
c
p
f
r
(
t
d
t
d
p
1
g
d
h
1
c
Grou
723JACC Vol. 49, No. 6, 2007 Mentzer, Jr. et al.
February 13, 2007:716–26 Nesiritide in Cardiac Surgery Patientshronic and acute renal insufficiency. More than 75% of
atients undergoing CABG in the U.S. have abnormal renal
unction at baseline; this is associated with an increased
isk-adjusted mortality odds ratio that ranges from 1.55
95% CI 1.45 to 1.65) for patients with moderate dysfunc-
ion to 3.82 (95% CI 3.45 to 4.25) for patients who are
ialysis dependent (14). In addition, depending on defini-
ions used, 25% to 30% of patients undergoing CABG
Figure 5 Kaplan-Meier Survival Curve to Day 180 by Treatment
Adverse Events
Table 5 Adverse Events
Overall summary
Any event
Any event classified as related to study drug
Any serious event
Any serious event classified as related to study drug
Any event causing withdrawal from the study
Cardiac, renal, and pulmonary adverse events
occurring in 5% of patients
Hypotension
Atrial fibrillation
Pleural effusion
Atelectasis
Peripheral edema
Acute renal failure*
Ventricular tachycardia
Respiratory failure
Sinus tachycardia
Dyspnea*Based on investigator classification without a predetermined requirement foevelop acute renal failure or dysfunction after surgery, and
ostoperative mortality in these patients is approximately
5% to 30% (10,12,13). In 843 consecutive patients under-
oing cardiac surgery with CPB, acute postoperative renal
ysfunction significantly increased mortality risk both in-
ospital (HR 12.6; 95% CI 5.7 to 27.0) and long-term (HR
.83; 95% CI 1.38 to 3.20) (13). Similarly, in 2,672
onsecutive patients undergoing CABG, in-hospital mor-
p in the Safety Population
Placebo Nesiritide
p Value
(n  138) (n  141)
n (%) n (%)
123 (89.1) 132 (93.6) 0.205
27 (19.6) 32 (22.7) 0.560
51 (37.0) 43 (30.5) 0.258
6 (4.3) 2 (1.4) 0.170
5 (3.6) 5 (3.5) 1.000
43 (31.2) 36 (25.5) 0.352
44 (31.9) 30 (21.3) 0.057
31 (22.5) 30 (21.3) 0.885
28 (20.3) 24 (17.0) 0.540
15 (10.9) 13 (9.2) 0.694
17 (12.3) 10 (7.1) 0.160
11 (8.0) 14 (9.9) 0.676
16 (11.6) 3 (2.1) 0.002
11 (8.0) 7 (5.0) 0.339
7 (5.1) 9 (6.4) 0.798r dialysis.
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Nesiritide in Cardiac Surgery Patients February 13, 2007:716–26ality was 28% in patients with acute renal failure and 12%
n patients with acute renal dysfunction, compared with 1%
n patients with neither (12). Furthermore, the mortality
isk associated with an acute decrease in renal function
ncreases with declining baseline renal function. In 2,067
onsecutive patients undergoing CABG, an additional acute
0 ml/min/1.73 m2 decrease in GFR increased mortality
isk by 67%, 40%, and 17% in patients with baseline GFR
f 20, 40, and 60 ml/min/1.73 m2, respectively (20).
Pre- and postoperative renal dysfunction also prolongs
ospital LOS (10,14,21). Preoperative renal failure was 1 of
significant multivariate predictors of prolonged LOS in an
valuation of 194 patients undergoing CABG (21), and
ostoperative acute renal failure and renal dysfunction
ignificantly prolonged both ICU LOS (acute renal failure:
4.9 days; postoperative renal dysfunction: 6.5 days; neither:
.1 days) and total hospital LOS (acute renal failure: 28.8
ays; postoperative renal dysfunction: 18.2 days; neither:
0.6 days) in 2,222 patients undergoing myocardial revas-
ularization (10). Consequently, preserving renal function
re- and postoperatively is an important component of
mproving clinical outcomes in patients undergoing cardiac
urgery.
Several therapeutic strategies for preserving renal func-
ion after cardiac surgery have been investigated, but to date
one have been proven effective. In separate evaluations,
ntravenous administration of N-acetylcysteine (11) and
renal-dose” dopamine (18) were found no more effective
han placebo, and intravenous fenoldopam was no more
ffective than “renal-dose” dopamine (17).
The observation in this study that no significant differ-
nces were detected in either pulmonary or systemic hemo-
ynamic parameters or in use of concomitant medications
ight be explained by the fact that nesiritide or placebo was
dded to usual care, as determined by the patient’s attending
hysician. The use of intravenous fluids and multiple
asoactive drugs, with adjustments made in response to
emodynamic monitoring in the immediate postoperative
eriod, could also explain the similarity of postoperative
emodynamic findings in the 2 treatment groups. Although
he number and class of drugs initially used were similar
etween treatment groups, intensity of drug exposure, as
ndicated by dose and duration, was not assessed. Differ-
nces in exposure intensity might account for some of the
bserved differences between treatment groups in this study.
Several physiologic mechanisms might account for the
bserved beneficial effects of nesiritide on renal function. In
randomized, placebo-controlled evaluation of patients
ndergoing CABG, infusion of human atrial natriuretic
eptide (ANP), initiated at the start of CPB and continued
or 24 h, significantly blunted bypass-associated neurohor-
onal activation, maintained GFR, improved urine output,
nd reduced the prevalence of postoperative renal insuffi-
iency (22). Nesiritide has neurohormonal effects that are
imilar to those of ANP. It inhibits sympathetic overactiv-
ty, decreasing circulating as well as local cardiac and renal rorepinephrine levels (5,23). It inhibits both the renin-
ngiotensin-aldosterone system, reducing both renin and
ldosterone levels (2,5,24–29), and endothelin-1, a potent
timulant of both vasoconstriction and sodium retention
6,27).
In healthy volunteers, nesiritide increases GFR and pro-
uces dose-dependent diuresis and natriuresis (24–26). In
atients with heart failure, it maintains renal blood flow
nd/or GFR (5,26,30,31) and either maintains (5,31) or
ncreases urinary sodium and/or water excretion (2,26,30).
The beneficial renal effects of nesiritide observed in this
tudy differ from those reported previously in medical
atients with acute decompensated heart failure. In a
andomized, controlled clinical trial of 489 patients with
cute decompensated heart failure, nesiritide improved he-
odynamic and clinical status but had no effect on SCr
evels in patients with or without renal insufficiency at
aseline (1). Similarly, nesiritide had no effect (positive or
egative) on GFR or urine output in a crossover study of 15
atients with heart failure and worsening SCr levels (31). In
ddition, a meta-analysis of data from 5 trials suggests that
esiritide therapy might be associated with an increased risk
f acute SCr elevation 0.5 mg/dl in patients with heart
ailure (32). The reasons for these differences are unknown
nd might be related to several factors, including differences
n baseline renal dysfunction, differences in nesiritide dose
dministered, and differing disease states in the various
rials. Although all patients in the current evaluation had
V dysfunction and serum B-type natriuretic peptide levels
onsistent with advanced heart failure, the patients were not
cutely decompensated at the time of surgery. In addition,
actors such as heightened catecholamine release during and
fter surgery, differences in nesiritide dosing regimen (e.g.,
ack of bolus and no increase in dose in response to systemic
r pulmonary hypertension), and extensive concomitant
erioperative use of vasoactive drugs (especially norepineph-
ine and vasopressin to support blood pressure) that would
ot be routinely employed in medical patients with acute
ecompensated heart failure might have influenced the renal
ffects of nesiritide in the current evaluation.
Alternatively, the effects of nesiritide in the present study
ight reflect the sequence of drug administration. In a
revious study, Sica et al. (33) showed that initiation of a
esiritide infusion before administration of intravenous
urosemide effectively blocked aldosterone release, whereas
urosemide alone elicited marked increases in plasma aldo-
terone. It is also possible that nesiritide has more specific
enal or neurohormonal effects in patients undergoing
ABG using CPB than in medical patients with acute
ecompensated heart failure. Finally, because intensity of
xposure to concomitant medications is unknown, subjects
ho received nesiritide might simply have had less exposure
o concomitant medications with possible adverse renal
ffects.
tudy limitations. The limitations of this study include the
elatively small sample size and the fact that usual-care
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February 13, 2007:716–26 Nesiritide in Cardiac Surgery Patientsedications and other treatment interventions were not
pecified in the protocol. Concomitant medications varied
reatly, depending on the attending physician’s assessment
f the patient’s clinical status, and there might have been
ndetected differences between treatment groups in addi-
ion to the study drug. Patients enrolled in this study
epresent only a subset of patients undergoing CABG at
articipating institutions, and it is impossible to determine
ow closely this subset reflects the overall patient population
t these institutions. Finally, the 180-day mortality end
oint was added late in the study as an additional safety end
oint, after the investigators became aware of concerns that
esiritide might be associated with an increased mortality
isk in patients with acutely decompensated heart failure. As
result, some subjects were lost to follow-up or declined
onsent for this later evaluation, leading to censored data.
he degree of censoring was similar in both study groups,
nd the mortality HR was relatively preserved over the
80-day study period. However, the possibility that the
ignificant reduction in 180-day mortality observed in pa-
ients who received nesiritide represents a type I error
annot be excluded. Finally, this was an exploratory study,
nd formal adjustment for multiplicity was not made; any
onclusions recognize the limitations due to multiple hy-
otheses being tested.
onclusions. Administration of nesiritide to patients with
V dysfunction undergoing CABG using CPB improved
ostoperative renal function, as indicated by a smaller
aximal increase in peak SCr, better preservation of GFR,
nd greater urine output in the immediate postoperative
eriod. These beneficial effects were enhanced in patients
ith preoperative renal dysfunction and were observed
espite the absence of significant hemodynamic changes. In
ddition, nesiritide treatment was associated with reduced
ospital LOS and decreased mortality at 180 days. Al-
hough the most likely explanation for the salutary effects of
esiritide administration on patient outcomes in the NAPA
rial seems to be prevention or attenuation of postoperative
enal dysfunction, additional studies are needed to confirm
hese findings.
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